Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease

Trial Identifier: D9230C00003
Sponsor: AstraZeneca
Start Date: August 2022
Primary Completion Date: November 2023
Study Completion Date: February 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Spanish (United States) Translation

Trial Locations

Country Location
US, TX San Antonio, TX, US, 78215